

8 October 2025

Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")

Director/PDMR and PCA Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 7 October 2025 that on 6 October 2025 Eddie Johnson, who is a Director and PDMR, transferred, through sale of 18,726 Ordinary Shares of 5p held on his behalf by Computershare Investor Services Plc ("Nominee"), at a price of 219.98p and repurchase of a total of 18,586 Ordinary Shares, by Individual Savings Accounts ("ISA's") held in the name of Eddie Johnson and Jackie Johnson, wife of Eddie Johnson, at a price of 219.90p per Ordinary Share to Eddie Johnson and 221.10p per Ordinary Share to Jackie Johnson.

Following these transactions, Eddie Johnson and Persons Closely Associated with him are interested in 313,498 Shares in the Company, representing 0.14 per cent. of the issued share capital of the Company. These transactions are part of normalised tax planning.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

1. Details of the person discharging managerial responsibilities/person closely associated				
a) Name: (i) Eddie Johnson (ii) Jackie Johnson				
2. Reason for the notification				
a) Position/status: (i) Chief Financial Officer (ii) Wife of Eddie Johnson				
b) Initial notification/Amendment: Initial Notification				
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a) Name: Advanced Medical Solutions Group plc				
b) LEI: 213800HJP6OWOSZ1L74				
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted				
a) Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594				
b) Nature of the transactions: · (i) Sale of 18,726 Ordinary Shares of 5p held in the name of the Nominee · (ii) Purchase of 9,546 Ordinary Shares of 5p into ISA's held in the name of Eddie Johnson · (iii) Purchase of 9,040 Ordinary Shares of 5p into ISA's held in the name of Jackie Johnson				
c) Price(s) and volume(s):				
<table border="1"><thead><tr><th>Price(s)</th><th>Volume(s)</th></tr></thead><tbody><tr><td></td><td></td></tr></tbody></table>	Price(s)	Volume(s)		
Price(s)	Volume(s)			

	(i) 219.98p	18,726	
	(ii) 219.90p	9,546	
	(iii) 221.10p	9,040	
d)	Aggregated information: Aggregated volume: (i) 18,726 (ii-iii) 18,586 Aggregated price: (i) 219.98p (ii-iii) 220.48p		
e)	Date of the transaction: 06/10/2025		
f)	Place of the transaction: London Stock Exchange, AIM Market (LON)		

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer
 Eddie Johnson, Chief Financial Officer
 Michael King, Investor Relations

Tel: +44 (0) 1606 545508

Optimum Strategic Communications

Mary Clark / Nick Bastin / Isabelle Abdou

Tel: +44 (0) 20 4566 8543

AMS@optimumcomms.com

Investec Bank PLC (NOMAD & Broker)

Gary Clarence / David Anderson

Tel: +44 (0) 20 7597 5970

Berenberg (Joint Broker)

Toby Flaux / Detlir Elezi / Yasmina Benchekroun

Tel: +44 (0)20 3207 7800

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver algimates, algimates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,600 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seq.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBUBDGDBGDGUI